References
- Bolleddula J, Brady K, Bruin G, Lee A, Martin JA, Walles M, Xu K, Yang TY, Zhu X, Yu H. 2022. Absorption, distribution, metabolism, and excretion (ADME) of therapeutic proteins: a white paper on current industry practices and future perspectives. Drug Metab Dispos. 50(6):837–845.
- EMA 2008. ICH Topic M 3 (R2). Note for the guidance on non-clinical safety studies for the conduct of human clinical trials and marketing authorisation for pharmaceuticals.
- FDA. 2020. Safety testing of drug metabolites: guidance for industry. Silver Spring (MD): FDA.
- FDA. 2022. Clinical pharmacology considerations for human radiolabeled mass balance studies. Draft guidance. Silver Spring (MD): FDA.
- Fernández-Maestre R, Doerr M. 2022. On the separation of enantiomers by drift tube ion mobility spectrometry. Anal Methods. 14(31):3011–3020.
- Husser C, Pähler A, Seymour M, Kuhlmann O, Schadt S, Zell M. 2018. Profiling of dalcetrapib metabolites in human plasma by accelerator mass spectrometry and investigation of the free phenothiol by derivatisation with methylacrylate. J Pharm Biomed Anal. 152:143–154.
- Schadt S, Hauri S, Lopes F, Edelmann MR, Staack RF, Villaseñor R, Kettenberger H, Roth AB, Schuler F, Richter WF, et al. 2019. Are biotransformation studies of therapeutic proteins needed? Scientific considerations and technical challenges. Drug Metab Dispos. 47(12):1443–1456.
- Walles M, Berna M, Jian W, Hauri S, Hengel S, King L, Tran JC, Wei C, Xu K, Zhu X. 2022. A cross company perspective on the assessment of therapeutic protein biotransformation. Drug Metab Dispos. 50(6):846–857.
- Young GC, Spracklin DK, James AD, Hvenegaard MG, Scarfe G, Wagner DS, Georgi K, Schieferstein H, Bjornsdottir I, van Groen B, et al. 2022. Considerations for human ADME strategy and design paradigm shift(s) – an industry white paper. Clin Pharmacol Ther.